Alpine Global Management’s Cymabay Therapeutics CBAY Stock Holding History

Alpine Global Management’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-197,888	Closed	-$584K	–	515
2022 Q2	$584K	Sell	197,888 -52,112	-21%	-$124K	0.15%	73
2022 Q1	$778K	Hold	250,000	–	–	0.18%	85
2021 Q4	$845K	Buy	+250,000	New	+$949K	0.12%	168
2021 Q1	–	Sell	-25,339	Closed	-$145K	–	375
2020 Q4	$145K	Buy	+25,339	New	+$192K	0.03%	141
2018 Q2	–	Sell	-14,933	Closed	-$194K	–	125
2018 Q1	$194K	Sell	14,933 -18,864	-56%	-$234K	0.05%	88
2017 Q4	$311K	Buy	+33,797	New	+$289K	0.07%	105

Other funds holding CBAY

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return

ACM

Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return

Alpine Global Management's CBAY Position: Q3 2022 in Review

Alpine Global Management sold out of Cymabay Therapeutics (CBAY) in Q3 2022, closing a stake of 197,888 shares — an estimated $584K sold.

Alpine Global Management first reported a position in CBAY in Q4 2017 and held it in 6 quarters. The position peaked at $845K in Q4 2021. 100 funds tracked by Wall St. Rank hold CBAY as of Q3 2022.

Alpine Global Management reported no remaining Cymabay Therapeutics position as of Q3 2022 after selling out during the quarter.
Alpine Global Management sold 197,888 Cymabay Therapeutics shares in Q3 2022, an estimated $584K.
Alpine Global Management first reported a position in Cymabay Therapeutics in Q4 2017 and held it in 6 quarters.
Alpine Global Management's Cymabay Therapeutics position peaked at $845K in Q4 2021.
100 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q3 2022.

Based on Alpine Global Management's 13F filing for Q3 2022, filed 14 Nov 2022.